Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma

Detailed Summary

Background: * Alveolar soft part sarcoma is a type of cancer that develops in tissues that connect, support, or surround other organs in the body. It relies heavily on new blood vessels to grow and spread through the body. There is no effective systemic treatment for patients with alveolar soft part sarcoma. * The drug AZD2171 (cediranib) is an experimental drug, not yet approved by the Food and Drug Administration. The drug blocks the creation of new blood vessels. The drug has had initial clinical trials, and researchers are interested in determining whether cediranib is effective in inhibiting tumor growth in individuals who have alveolar soft part sarcoma. Objectives: \- To find out whether AZD2171 works in patients who have alveolar soft part sarcoma. Eligibility: \- Individuals 18 years of age and older who have been diagnosed with alveolar soft part sarcoma. Design: * After an initial screening visit, patients will take AZD2171 by mouth once a day, every day for the duration of the study. The treatment will be given in 28-day cycles. * Patients will keep a study diary to record the doses taken, any missed doses, and any side effects. * Patients will have the following tests and procedures during the treatment period: clinic visit with physical examination every 2 weeks during cycles 1 and 2, then at the start of each subsequent cycle, regular blood pressure monitoring, blood and urine tests, heart function tests, imagining scans to evaluate tumor size and response to the treatment, and possible tumor biopsy.

Study Details

Timeline

Interventions